Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Condition Directory

Ovarian Cancer clinical trials

Directory of U.S. ClinicalTrials.gov public records for Ovarian Cancer. Browse Ovarian Cancer recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 17, 2026 Report an issue

ClinicalTrials.gov public records Last synced Oct 17, 2026, 5:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
740
Shown on this page
12
Current sort
Recently updated
Condition scope
Ovarian Cancer
Additional filters apply within this condition.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

How Ovarian Cancer studies are organized in the registry

Ovarian cancer records are commonly registered as a group — “ovarian, fallopian tube, or primary peritoneal cancer” — so the broader phrasing is normal and not a labeling error. Platinum-sensitivity language (“platinum-resistant,” “platinum-sensitive”) and BRCA status frequently define the study population in titles.

Terms that often appear in related listings
platinum-resistant fallopian tube BRCA PARP

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Filter and sort this condition

These controls apply only within Ovarian Cancer. Default order is Recently updated. Add location, sponsor, treatment, or recruitment status to narrow this condition page further.

Reset condition filters
Clear filters
Showing 637–648 of 740 matching trials for Ovarian Cancer.
Live ClinicalTrials.gov results.
Active filters: "fallopian tube" Clear condition filters
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Completed Phase 2 Interventional Results available

Study of Gemcitabine/Carboplatin/Bevacizumab to Treat Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT00267696
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions
Bevacizumab, Gemcitabine, Carboplatin
Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Oct 17, 2026, 5:59 PM EDT
Completed Phase 1 Interventional

Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors

NCT00066651
View directory record Official record
Conditions
Cervical Cancer, Fallopian Tube Cancer, Head and Neck Cancer, Lung Cancer, Malignant Mesothelioma, Ovarian Cancer, Pancreatic Cancer, Primary Peritoneal Cavity Cancer
Interventions
SS1(dsFv)-PE38 immunotoxin
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
2
States / cities
Bethesda, Maryland • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Oct 17, 2026, 5:59 PM EDT
Completed Phase 2 Interventional

Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumor

NCT00039585
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
imatinib mesylate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Oct 17, 2026, 5:59 PM EDT
Completed Phase 2 Interventional

Pilot Study of Taxol, Carboplatin, and Bevacizumab in Advanced Stage Ovarian Carcinoma Patients

NCT00127920
View directory record Official record
Conditions
Ovarian Neoplasms
Interventions
Avastin
Drug
Lead sponsor
Gynecologic Oncology Associates
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
2
States / cities
Newport Beach, California • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 10, 2015 · Synced Oct 17, 2026, 5:59 PM EDT
Completed Phase 1 Interventional

Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer

NCT00352300
View directory record Official record
Conditions
Fallopian Tube Carcinoma, Infectious Disorder, Neutropenia, Ovarian Carcinosarcoma, Primary Peritoneal Carcinoma, Stage III Ovarian Cancer, Stage IV Ovarian Cancer
Interventions
Adjuvant Therapy, Carboplatin, Paclitaxel, Pegfilgrastim
Procedure · Drug · Biological
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
11
States / cities
Orange, California • Iowa City, Iowa • Camden, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2014 · Synced Oct 17, 2026, 5:59 PM EDT
Completed Phase 1 Interventional

Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer

NCT00814086
View directory record Official record
Conditions
Chemotherapeutic Agent Toxicity, Endometrial Adenocarcinoma, Fallopian Tube Carcinoma, Gastrointestinal Complication, Malignant Ovarian Mixed Epithelial Tumor, Neurotoxicity Syndrome, Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Primary Peritoneal Carcinoma, Stage II Ovarian Cancer, Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Undifferentiated Ovarian Carcinoma
Interventions
Paclitaxel, Cisplatin
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
7
States / cities
Chicago, Illinois • Iowa City, Iowa • Camden, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2014 · Synced Oct 17, 2026, 5:59 PM EDT
Completed Phase 1 Interventional

TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

NCT01294293
View directory record Official record
Conditions
Malignant Ovarian Mixed Epithelial Tumor, Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Undifferentiated Ovarian Carcinoma
Interventions
TLR8 Agonist VTX-2337, Diagnostic Laboratory Biomarker Analysis, Pharmacological Study, Pegylated Liposomal Doxorubicin Hydrochloride, Paclitaxel
Drug · Other
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
10
States / cities
Phoenix, Arizona • Aurora, Colorado • Iowa City, Iowa + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 25, 2014 · Synced Oct 17, 2026, 5:59 PM EDT
Completed Not applicable Interventional

Early Intervention vs. Standard Palliative Care in Improving End-of-Life Care in Advanced Cancer Patients

NCT00253383
View directory record Official record
Conditions
Cancer
Interventions
counseling intervention, educational intervention, psychosocial assessment and care, quality-of-life assessment
Other · Procedure
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
2
States / cities
Lebanon, New Hampshire • White River Junction, Vermont
Source: ClinicalTrials.gov public record
Updated Dec 19, 2014 · Synced Oct 17, 2026, 5:59 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Short Non-coding RNA Biomarkers of Predisposition to Ovarian Cancer

NCT01187602
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Not listed
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 5, 2014 · Synced Oct 17, 2026, 5:59 PM EDT
Completed Phase 3 Interventional

S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission

NCT00003120
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
Interventions
paclitaxel
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older · Female only
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2012
U.S. locations
93
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2014 · Synced Oct 17, 2026, 5:59 PM EDT
Terminated No phase listed Observational

Effect of Serotonin Level on Constipation Caused by Chemotherapy in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT00536523
View directory record Official record
Conditions
Constipation, Bowel Obstruction, Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 22, 2014 · Synced Oct 17, 2026, 5:59 PM EDT
Terminated Phase 2 Interventional Results available

Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma

NCT00418093
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions
Gemcitabine, Oxaliplatin, Bevacizumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 19, 2014 · Synced Oct 17, 2026, 5:59 PM EDT

About this Ovarian Cancer clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Ovarian Cancer as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results
Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Ovarian Cancer.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Ovarian Cancer.